Risk-stratification Model to Select Conversion Surgery for Advanced Gastric Cancer Patients

Runcong Nie,Shuqiang Yuan,Yuanfang Li,Shi Chen,Shuman Li,Lirong Yang,Lifang Yang,Yingbo Chen,Zhiwei Zhou
DOI: https://doi.org/10.21147/j.issn.1000-9604.2019.01.13
2019-01-01
Chinese Journal of Cancer Research
Abstract:Objective Conversion surgery is a surgery with a purpose of R0 resection in primary advanced gastric cancer (GC) that responded well to systemic chemotherapy. This study aimed to explore the efficacy of conversion surgery for advanced GC. Methods A total of 618 advanced GC patients receiving systemic chemotherapy were stratified into low-, moderate- and high-risk groups based on a nomogram-predicted probability of overall survival. The survival of conversion surgery and chemotherapy alone groups was compared using the log-rank test and Cox regression analysis after propensity score matching (PSM). Results A nomogram with good discrimination (concordance index: 0.65) and accurate calibration was constructed. After PSM, the median survival time (MST) of conversion surgery was 26.80 months, compared with 16.60 months of chemotherapy alone (P<0.001). Conversion surgery was associated with a longer MST for patients in the low-risk group (30.40 monthsvs. 20.90 months, P=0.013), whereas it was not associated with prolonged survival in the moderate- and high-risk groups (P=0.221 and P=0.131, respectively). Conclusions Conversion surgery was associated with longer survival, especially for low-risk population.
What problem does this paper attempt to address?